Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 8Sarcopenia 2Prostatic Neoplasms 2Obesity 2Melanoma 2Malnutrition 2Colorectal Neoplasms 2Breast Carcinoma In Situ 2Wound Infection 1Weight Loss 1Surgical Wound Infection 1Skin Neoplasms 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Polycystic Ovary Syndrome 1Phagocyte Bactericidal Dysfunction 1Pain 1Paget's Disease, Mammary 1Osteoarthritis 1Olfaction Disorders 1Neoplasms 1Neoplasm, Residual 1Mandibular Neoplasms 1Lymphoma, Follicular 1Lipid Metabolism Disorders 1Huntington Disease 1Fatigue 1Diabetes Mellitus 1

Interventions

eicosapentaenoic acid ethyl ester 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Huntington Disease × Docosahexaenoic Acids × Clear all
NCT00146211 2007-12-27

TREND-HD - A Trial of Ethyl-EPA (Miraxionâ„¢) in Treating Mild to Moderate Huntington's Disease

Amarin Neuroscience Ltd

Phase 3 Completed
300 enrolled
Lymphoid

Huntington Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡